查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1556598

轉移性大腸直腸癌市場：趨勢、預測和競爭分析（~2030 年）

Metastatic Colorectal Cancer Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

預計2024年至2030年全球轉移性大腸直腸癌市場規模將以4.3%的複合年成長率成長。該市場的主要促進因素是全球轉移性大腸直腸癌盛行率的不斷上升、癌症研究的不斷進步以及單株抗體等標靶治療的引入。全球轉移性大腸直腸癌市場的未來充滿希望，醫院、癌症中心和門診手術中心市場充滿機會。

轉移性大腸直腸癌分段預測

全球轉移性大腸直腸癌市場的預測按治療、藥物類別、最終用途和地區提供。

轉移性大腸直腸癌市場洞察

預計化療在預測期內將出現最高成長。

在這個市場中，醫院治療預計將在預測期內實現最高成長。

預計北美地區在預測期內將出現最高的成長。

常問問題

Q1.市場成長預測是多少：

A1. 2024年至2030年，全球轉移性大腸癌市場預計將以4.3%的複合年成長率成長。

Q2. 影響市場成長的關鍵促進因素是：

A2. 該市場的主要驅動力是全球轉移性結直腸癌盛行率的不斷上升、癌症研究的不斷進步以及單株抗體等標靶治療的引入。

Q3.市場的主要細分市場是：

A3. 轉移性大腸直腸癌市場前景廣闊，醫院、癌症中心和門診手術中心市場充滿機會。

Q4.市場的主要企業是：

A4. 轉移性大腸直腸癌的主要企業如下：

  • Amgen
  • EMD Serono
  • Eli Lilly
  • Genentech
  • Novartis
  • Pfizer
  • F. Hoffmann-La Roche
  • Sanofi
  • Suzhou Zelgen Biopharmaceuticals
  • Taiho Oncology

Q5.未來最大的細分市場是什麼？

A5.我們預計化療將在預測期內達到最高成長。

Q6.未來五年預計哪些地區的市場成長最大？

A6. 預計北美地區在預測期內將出現最高成長。

Q7. 可以客製化報告嗎？

A7. 是的，我們提供 10% 的客製化服務，無需額外費用。

目錄

第1章執行摘要

第2章全球轉移性大腸直腸癌市場：市場動態

  • 簡介、背景、分類
  • 供應鏈
  • 產業促進因素與挑戰

第3章 2018-2030年市場趨勢及預測分析

  • 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
  • 全球轉移性大腸直腸癌市場趨勢（2018-2023）與預測（2024-2030）
  • 全球轉移性大腸直腸癌市場：依治療分類
    • 化療
    • 標靶治療
    • 免疫療法
    • 單一療法/聯合治療
    • 其他
  • 全球轉移性大腸直腸癌市場：依藥物類別
    • 抗EGFR抑制劑
    • 抗VEGF治療
    • 抗 HER2 治療
    • 免疫查核點抑制劑
    • 其他
  • 全球轉移性大腸直腸癌市場：依最終用途分類
    • 醫院
    • 癌症中心
    • 門診手術中心
    • 其他

第 4 章 2018-2030 年按地區分類的市場趨勢與預測分析

  • 全球轉移性大腸直腸癌市場：按地區
  • 北美轉移性大腸直腸癌市場
  • 歐洲轉移性大腸直腸癌市場
  • 亞太地區轉移性大腸直腸癌市場
  • 其他地區轉移性大腸直腸癌市場

第5章 競爭分析

  • 產品系列分析
  • 營運整合
  • 波特五力分析

第6章 成長機會與策略分析

  • 成長機會分析
    • 透過治療
    • 按藥品類別
    • 按最終用途
    • 按地區
  • 全球轉移性大腸直腸癌市場的新興趨勢
  • 戰略分析
    • 新產品開發
    • 全球轉移性大腸直腸癌市場的產能擴張
    • 全球轉移性大腸直腸癌市場的合併、收購和合資企業
    • 認證和許可

第7章主要企業概況

  • Amgen
  • EMD Serono
  • Eli Lilly
  • Genentech
  • Novartis
  • Pfizer
  • F. Hoffmann-La Roche
  • Sanofi
  • Suzhou Zelgen Biopharmaceuticals
  • Taiho Oncology
簡介目錄

Metastatic Colorectal Cancer Trends and Forecast

The future of the global metastatic colorectal cancer market looks promising with opportunities in the hospital, cancer center, and ambulatory surgical center markets. The global metastatic colorectal cancer market is expected to grow with a CAGR of 4.3% from 2024 to 2030. The major drivers for this market are growing incidence of metastatic colorectal cancer globally, rising advancements in cancer research, and introduction of targeted therapies such as monoclonal antibodies.

A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.

Metastatic Colorectal Cancer by Segment

The study includes a forecast for the global metastatic colorectal cancer by treatment, drug class, end use, and region.

Metastatic Colorectal Cancer Market by Treatment [Shipment Analysis by Value from 2018 to 2030]:

  • Chemotherapy
  • Targeted Therapies
  • Immunotherapies
  • Monotherapy & Combination Therapy
  • Others

Metastatic Colorectal Cancer Market by Drug Class [Shipment Analysis by Value from 2018 to 2030]:

  • Anti-EGFR Inhibitors
  • Anti-VEGF Therapies
  • Anti-HER2 Therapies
  • Immune Checkpoint Inhibitors
  • Others

Metastatic Colorectal Cancer Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals
  • Cancer Centers
  • Ambulatory Surgical Centers
  • Others

Metastatic Colorectal Cancer Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Metastatic Colorectal Cancer Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies metastatic colorectal cancer companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the metastatic colorectal cancer companies profiled in this report include-

  • Amgen
  • EMD Serono
  • Eli Lilly
  • Genentech
  • Novartis
  • Pfizer
  • F. Hoffmann-La Roche
  • Sanofi
  • Suzhou Zelgen Biopharmaceuticals
  • Taiho Oncology

Metastatic Colorectal Cancer Market Insights

Lucintel forecasts that chemotherapy is expected to witness the highest growth over the forecast period.

Within this market, hospital is expected to witness the highest growth over the forecast period.

North America is expected to witness the highest growth over the forecast period.

Features of the Global Metastatic Colorectal Cancer Market

Market Size Estimates: Metastatic colorectal cancer market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Metastatic colorectal cancer market size by treatment, drug class, end use, and region in terms of value ($B).

Regional Analysis: Metastatic colorectal cancer market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different treatments, drug classes, end uses, and regions for the metastatic colorectal cancer market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the metastatic colorectal cancer market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the growth forecast for metastatic colorectal cancer market?

Answer: The global metastatic colorectal cancer market is expected to grow with a CAGR of 4.3% from 2024 to 2030.

Q2. What are the major drivers influencing the growth of the metastatic colorectal cancer market?

Answer: The major drivers for this market are growing incidence of metastatic colorectal cancer globally, rising advancements in cancer research, and introduction of targeted therapies such as monoclonal antibodies.

Q3. What are the major segments for metastatic colorectal cancer market?

Answer: The future of the metastatic colorectal cancer market looks promising with opportunities in the hospital, cancer center, and ambulatory surgical center markets.

Q4. Who are the key metastatic colorectal cancer market companies?

Answer: Some of the key metastatic colorectal cancer companies are as follows:

  • Amgen
  • EMD Serono
  • Eli Lilly
  • Genentech
  • Novartis
  • Pfizer
  • F. Hoffmann-La Roche
  • Sanofi
  • Suzhou Zelgen Biopharmaceuticals
  • Taiho Oncology

Q5. Which metastatic colorectal cancer market segment will be the largest in future?

Answer: Lucintel forecasts that chemotherapy is expected to witness the highest growth over the forecast period.

Q6. In metastatic colorectal cancer market, which region is expected to be the largest in next 5 years?

Answer: North America is expected to witness the highest growth over the forecast period.

Q7. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the metastatic colorectal cancer market by treatment (chemotherapy, targeted therapies, immunotherapies, monotherapy & combination therapy, and others), drug class (anti-EGFR inhibitors, anti-VEGF therapies, anti-HER2 therapies, immune checkpoint inhibitors, and others), end use (hospitals, cancer centers, ambulatory surgical centers, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Metastatic Colorectal Cancer Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Metastatic Colorectal Cancer Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Metastatic Colorectal Cancer Market by Treatment
    • 3.3.1: Chemotherapy
    • 3.3.2: Targeted Therapies
    • 3.3.3: Immunotherapies
    • 3.3.4: Monotherapy & Combination Therapy
    • 3.3.5: Others
  • 3.4: Global Metastatic Colorectal Cancer Market by Drug Class
    • 3.4.1: Anti-EGFR Inhibitors
    • 3.4.2: Anti-VEGF Therapies
    • 3.4.3: Anti-HER2 Therapies
    • 3.4.4: Immune Checkpoint Inhibitors
    • 3.4.5: Others
  • 3.5: Global Metastatic Colorectal Cancer Market by End Use
    • 3.5.1: Hospitals
    • 3.5.2: Cancer Centers
    • 3.5.3: Ambulatory Surgical Centers
    • 3.5.4: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Metastatic Colorectal Cancer Market by Region
  • 4.2: North American Metastatic Colorectal Cancer Market
    • 4.2.1: North American Metastatic Colorectal Cancer Market by Treatment: Chemotherapy, Targeted Therapies, Immunotherapies, Monotherapy & Combination Therapy, and Others
    • 4.2.2: North American Metastatic Colorectal Cancer Market by End Use: Hospitals, Cancer Centers, Ambulatory Surgical Centers, and Others
  • 4.3: European Metastatic Colorectal Cancer Market
    • 4.3.1: European Metastatic Colorectal Cancer Market by Treatment: Chemotherapy, Targeted Therapies, Immunotherapies, Monotherapy & Combination Therapy, and Others
    • 4.3.2: European Metastatic Colorectal Cancer Market by End Use: Hospitals, Cancer Centers, Ambulatory Surgical Centers, and Others
  • 4.4: APAC Metastatic Colorectal Cancer Market
    • 4.4.1: APAC Metastatic Colorectal Cancer Market by Treatment: Chemotherapy, Targeted Therapies, Immunotherapies, Monotherapy & Combination Therapy, and Others
    • 4.4.2: APAC Metastatic Colorectal Cancer Market by End Use: Hospitals, Cancer Centers, Ambulatory Surgical Centers, and Others
  • 4.5: ROW Metastatic Colorectal Cancer Market
    • 4.5.1: ROW Metastatic Colorectal Cancer Market by Treatment: Chemotherapy, Targeted Therapies, Immunotherapies, Monotherapy & Combination Therapy, and Others
    • 4.5.2: ROW Metastatic Colorectal Cancer Market by End Use: Hospitals, Cancer Centers, Ambulatory Surgical Centers, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Metastatic Colorectal Cancer Market by Treatment
    • 6.1.2: Growth Opportunities for the Global Metastatic Colorectal Cancer Market by Drug Class
    • 6.1.3: Growth Opportunities for the Global Metastatic Colorectal Cancer Market by End Use
    • 6.1.4: Growth Opportunities for the Global Metastatic Colorectal Cancer Market by Region
  • 6.2: Emerging Trends in the Global Metastatic Colorectal Cancer Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Metastatic Colorectal Cancer Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Metastatic Colorectal Cancer Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Amgen
  • 7.2: EMD Serono
  • 7.3: Eli Lilly
  • 7.4: Genentech
  • 7.5: Novartis
  • 7.6: Pfizer
  • 7.7: F. Hoffmann-La Roche
  • 7.8: Sanofi
  • 7.9: Suzhou Zelgen Biopharmaceuticals
  • 7.10: Taiho Oncology